Drug
Trofinetide clinical trials
Also written NNZ-2566.
- studies test it
- 12
- open now
- 0
- in phase 3
- 4
- first study started
- 2010
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
12 studies that test it; most in 2010 (2)
| Year | Studies |
|---|---|
| 2010 | 2 |
| 2012 | 1 |
| 2013 | 2 |
| 2014 | 2 |
| 2016 | 1 |
| 2019 | 1 |
| 2020 | 2 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 2
- Phase 2
- 7
- Phase 3
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 12 · Other 0
Neuren Pharmaceuticals Limited (8) · ACADIA Pharmaceuticals Inc. (4)
Studies
Open first, then newest update. How each study uses trofinetide is read from its arms, and is right about nine times in ten.
Testing it · 12
- Open-Label Extension Study of Trofinetide for Rett SyndromeTerminatedPhase 3ACADIA Pharmaceuticals Inc.NCT04776746Written as trofinetide
- An Open-Label Study of Trofinetide for the Treatment of Girls Two to Five Years of Age Who Have Rett SyndromeTerminatedPhase 2/3ACADIA Pharmaceuticals Inc.NCT04988867Written as Trofinetide
- Open-Label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett SyndromeCompletedPhase 3ACADIA Pharmaceuticals Inc.NCT04279314Written as Trofinetide
- Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™)CompletedPhase 3ACADIA Pharmaceuticals Inc.NCT04181723Written as Trofinetide
- A Safety Study of NNZ-2566 in Pediatric Rett SyndromeCompletedPhase 2Neuren Pharmaceuticals LimitedNCT02715115Written as NNZ-2566
- Study of NNZ-2566 in Patients With Traumatic Brain Injury Under EFICCompletedPhase 2Neuren Pharmaceuticals LimitedNCT01366820Written as NNZ-2566
- A Safety Study of NNZ-2566 in Patients With Fragile X SyndromeCompletedPhase 2Neuren Pharmaceuticals LimitedNCT01894958Written as NNZ-2566
- Study of NNZ-2566 in Patients With Traumatic Brain InjuryCompletedPhase 2Neuren Pharmaceuticals LimitedNCT00805818Written as NNZ-2566
- A Safety Study of NNZ-2566 in Patients With Rett SyndromeCompletedPhase 2Neuren Pharmaceuticals LimitedNCT01703533Written as NNZ-2566
- A Safety and Efficacy Study of NNZ-2566 in Patients With Mild Traumatic Brain Injury (mTBI)TerminatedPhase 2Neuren Pharmaceuticals LimitedNCT02100150Written as NNZ-2566
- Safety Study of NNZ-2566 in Healthy Female SubjectsCompletedPhase 1Neuren Pharmaceuticals LimitedNCT00961779Written as NNZ-2566
- Safety Study of NNZ-2566 in Healthy Subjects, Following Oral AdministrationCompletedPhase 1Neuren Pharmaceuticals LimitedNCT01420042Written as NNZ-2566
Codes
What other systems call trofinetide · ClinicalTrials.gg INT001245
- MeSH (NLM) C000656362trofinetideOne source NLM
- UNII (FDA) Z2ME8F52QLTROFINETIDEConfirmed FDA, NLM, Wikidata
- Wikidata Q27294917trofinetideConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152757TrofinetideOne source FDA
- DrugBank DB06045One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000656362 | trofinetide | One source NLM |
| UNII (FDA) | Z2ME8F52QL | TROFINETIDE | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27294917 | trofinetide | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152757 | Trofinetide | One source FDA |
| DrugBank | DB06045 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.